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Chapter l2
SUMMARY, GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Hereditary nonpolyposis colorectal cancer (HNPCC) is one of the most commonly
occurring hereditary conditions that lead to an increased risk for several tumor types, with the
highest lifetime risks for colorectal and endometrial cancer. In Chapter I a short historical
introduction is given conceming HNPCC. The formulation of clinical criteria in 1991, known
as the Amsterdam Criteria, were primarily meant to help research in this field by providing a
uniform dehnition of the disorder, but were soon also used to define families to be HNPCC-
families for clinical pu.poses.t These criteria include presence of (1) at least three relatives
with histologically verified cancer of the colorectum, one of whom is a frrst-degree relative of
the other two; (2) at least two successive generations affected; (3) at least one case diagnosed
under the age of 50 years; and (4) exclusion of familial adenomatous polyposis. The latter is
important as HNPCC lacks pathognomonic phenotlpic features. Therefore, tlre diagnosis
cannot be made in an individual purely based on individual characteristrcs.
Soon after the Amsterdam Critena were formulated, the rnismatch repair (MMR) genes
MSH2 and MLHI were identified and the association between germline mutations in these
genes and HNPCC, as clinically defined, was established.'-" More than half of the families
fulfiliing tl.re Amsterdam Criteria proved to harbor a gem.rlinc mutation in one of thesc two
genes and what was first a slmdrome just by clinical definit ion, could now bc l inked to a
genetic defect. Horvever, it becarne clear that only part of the patients and their lamilies that
carry a pathogenic MLHI or MSII2 mutatiorr fulfill the Amstcrdaur Criteria. This is duc to a
nunrber of factors: the occurrence of extracolonic anccrs in nrutation carriers, the diff iculty
to verify the cancer diagnosis in family menrbers that passed away a long time ago, a
decreasing average family size and the occurrence, though rare, of de noyo ntutations. Or.r the
other hand, large pedigrees may sometimes fulf i l l  the Amsterdam Criteria as the result of
accidental clustering of three first-degree relatives with carrccr. Germline nrutations in anothcr
hunran MMR genc, Í.l'te MSH6 gene, were reporled for the first time in 1991 in mer.nbcrs of
two families that did not fulf i l l  the Amstcrdam Criteria.s " This ivas another reason to realize
that thc Amsterdam Criteria were not sensitive er.rough to identi ly all mutation carriers.
Defectivc MMR functior-r is charactcriz,edby microsatcll i tc instabil ity (MSI) and by loss
of MMR protein exprcssion in the tumor tissue. Microsatell i tes are short repetit ive basc
sequences. Tunror cells deÍlcient in post-replication MMR function show an incrcase in thc
ratc of spontancous mutations, most readily scen in microsatell i tes, both ir.r non-coding and in
coding sequences, including seqllences in genes r.vhich are involvcd in the developntcnt and
progression of tumors, l ike the TGFIJRII ancl Brrr g.n.r.t Sincc alnrost all colorcctal cancers
fronr patierrts'"vit l i  an MLHI or an lvtSH2 mutation show nricrosatcli i te instabil it\ '8, MSI
analysis has been put foruard as a selection criterion for rnutation analysis. At an
international conference in Bethcsda, MD. USA. in 1996 conscnsus rvas rcachcd about
criteria to iderit ify patients whosc turnors shorrld bc tested for MSI arrd the Bcthesda cri leria
were introduced." To cnsure unifonrity, a rcfcrence panel of t l ie most scnsitive rl icrosatcll i tc
markers'uvas developcd and validated to perfomr MSI analysis in colorectal canccr.n Though a
valuable tooll ') ' l l ,  only a small nrinority of colorectal cancers and other tunrors exhibit ing
rricrosatell i te instabil ity are due to a germlinc mutalion in he MLIII or MSH2 gencs.' '
Sporadic cases of microsatcll i te instable cancers may be duc to sorratic inactivation of MMR
genes.
Besides MSl, immunohistochemical analysis for the two MMR proteins MLHI and
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dcten.ninc MSH6 protein expression is increasing.l6-le The two methods, MSI analysis and
irrmunohistochernical r.ralysis, are highly sensitive and provide the opportu-nity to sort out
r..,hich patient shor.rld be fr.rrlher analyzed forgenrrl ine MMR gene mutations.' '  Advanlages of
imnrunoli istocherlistry over MSI analysis include its nrore widespread availabil ity, lower
costs and the clirection it gives lor mutation analysis.
Idcntifying gcrmline MMR gcne rrrutations is imporlant as mutation carriers and their
familics are eligible for schenres for periodic screening to detect neoplasms at the earliest
possible stages. It has beerr shown thal pcriodic colonoscopy is useful and drastically reduces
colorectal canccr ti1ofiality.2()'21 IIone aims to cletect as many carriers with germline MMR
genc nrutations as possible, thc Amstcrdam Criteria appeared to bc not sensitive enough as
mentioncd above, and other ways of identif ication of patients and farnil ies were needed.
Thcrcl 'ore. othcr sets of clinical criteria besicles the Amsterdam Criteria were formulated ir.r
the past years to detect paticnts with a relevant gennline mutation with a high sensitivity, and
acceptable specifici ly and positive ancl ncgative prcdictive values. These criteria are reviewed
and discussed in Chapter 2. Each ol the proposed set of clinical criteria was less stringent
lhan thc Arnstcrdam Critcri l. bLrl the l icld of mutalions u,as usually lower than when using
ll ie Amsterdanr Critcria. FuÍhemrore, in most str.rdies the criteria were evaluated in only a
small number of subjects. It is apparently very diff icult to formulate optirnal criteria to select
those patients that are most suspcct for having a germline MMR gene mutation. The original
Amsterdam Criteria r"'cre extendcd in 1999 to includc those cxtracolonic cancers that showed
tl-re highest relative risk to occur iu nrutation carriers, i.e. cndomctrial cancer, small bowel
canccr ancl transitional cell cancer of t l.re rer.ral pelvis and ureter. These criteria werc cailed the
Amstcrclam Criteria II or revised Arnsterclanr critcria.rr According to a recent study the
relative mutation dctection ratc 01- thcsc criteria rvas about the samc comoarcd to the old
c r i t e r i a  (50% (1091217 )  vc rsus  52? l  ( l 0 l i  193 ) r cspec t i ve l y ) . r ' '
The goal  o1 ' th is  thesis  was threcfo ld as descr ibed in Chapter  l .  F i rs t  of  a l l ,  the
prcvii le;rcc oIgenrlinc mutations in thc ML[{], MSH2 ancl MS116 genes was detennined in
dil ' ferent patient populalions, suspected of HNPCC. Secondly, the outcome of the MSI
analysis ancl ir.nnrunohistocl.rerl icai analysis of t l.re three MMR protcins wcre studied in
relation to each other, to the results ol-the nrutation analysis and to the clinical data ar.rd lamily
history data in order to dctcmrinc indcpcnclcnt high risk variables for detecting putative MMR
gene r.nutation carricrs. Finally, the results of this study should help to fomrulatc accurate and
simple criteria for usc iu the clinical practice. Patients could participate in thc study when
iLrlf i l l ing one of the follorving criteria: (l) paticnls rvith colorectal cancer or endometrial
canccr diagnosed under 50 years of age; (2) patients '"vith an HNPCC-related cancer and a
Íirst-degrce relative ."r ' i th colorectal cancer or endonretrial cancer, or vice versa, onc of them
diagnosed under 50 years of age; (3) patients with two or morc HNPCC-related cancers,
inespective of agc or; (4) patients with a colorectal adenoma or atypical endometrial
hypcrplasia tl.rat have a first-degree rclative with colorectal cancer or endometrial cancer, both
diagnosed at an agc younger than 50 ycars. HNPCC-related cancers as defined in this study
*'erc colorectal cancer. er.rdometrial cancer. cancer of the small bowel. the stomach. the
pancreas, the bil iarytract and thc ovaries and transitional cell cancer ofthe renal pelvis, ureter
and bladder. Three large groups of patients emerged during the course of the study, namely
paticnts with colorectai cancer and patients r'vith endometrial cancer, all diagnosed under the
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age of 50 year (criterion 1), and patients with multiple HNPCC-related cancers, irrespective
ofage (criterion 3). Further analyses were focused on these three groups.
For two reasons, only the medical history conceming cancer of first-degree relatives was
included to make associations and calculations. Firstly, in clinical practice, selection criteria
should be as simple as possible. Secondly, medical histories of f irst-degree relatives can be
verified better than those of, for example, grandparents. However, to identily Amsterdam
families among the families of the patients in our study, data on lamily history were
completed up to the third degree, but there n-ray have been sonre bias because of incorrcct
information. Recently, the reliabil i ty of family history was investigated in a total of 1200
patients with colorectal cancer.'" That study suggested that family studies on HNPCC arc not
reliable unless the diagnoses of familymembers are verif ied from official soLlrccs. Both false-
positive family and false-negative family histories for the Amsterdam Criteria Il were
detected. Thus, verif ication of medical histories appears of vital importance.
In Chapter 3, the patients with colorectal cancer, diagnosed under the age of 50 years
are reported. Young age at diagnosis of colorectal cancer is an imporlant, independent
predictor of a n.rutalion in the MLHI or MSH: gene2s and is included in thc Amstcrdan.r
Criteria II." To identify better criteria 1o select young colorectal cancer patients for mutation
analysis in future, predictive values of f irst-degree fanrily history, turnor MSI analysis ancl
immunohistochernical nalysis of the three MMR proteins MLHI, MSH2 and MSH6 in
predicting pathogenic germlinc mutations were calculated and multivariate analysis was
performed. In 14 out of 224 young colorectal cancer paticnts (6%) a mutation was found
leading to truncation of the protein product and, therefore, considered as pathogenic. The
sensitivity of the Amsterdam Criteria II appeared to be low (29%) as only 4 of the 14
mutations detected were found amongst the 14 patients lrom (assumcd) Anrsterdanr families.
First-degree lamily history as well as MSI analysis and immunohistochemical nalysis were
good predictors to select patients possrbly having germline mutations. Whcn scleclion rvould
be based on family history alone, however, thrce rnutation caniers wor.rld have been missed,
whereas both MSI and immunohistochemical nalysis would have misscd one canicr.
Immunohistochemical analysis had a seemingly higher positive predictive value than
MSI-analysis, implying that less mutation analyses would be needcd rvhen relying upon thc
results of the immunohistochenrical nalysis. Muhivariate ar.ralysis for the aforcmentioncd
variables revealcd that immunohistochcmical analysis is the single bcst predictor to sclect
paticnts for the analysis of mutations as defined above. Thus, in patienls diagnoscd r.vith
colorectal cancer before the age of 50 ycars, MMR protein staining should be performed, in
particular when there is a positive first-degree family history lor HNPCC-related cancer(s).
When staining of at least onc MMR protein is absent, patients should then bc oflerccl nrutation
analysis of the non-expressed gene(s). The relativcly easy inmrunohislochemical techniquc
should become generally available to identify thc large nrajority of MMR gcne mutation
carriers among young colorectal cancer paticr.rts.
The same procedure tl iat was applied lor young colorcctal cancer paticnts rvas also uscd
for patients rvith multiplc HNPCC-related cancers. Chapter 4 dcscribes tl.re results of
gern.rl ine MMR genc nrutation analysis in 96 such palienls in relation to agc at diagnosis,
tumor tlpcs, family history, arrd tumor MSI and MMR protcir.r cxpression in the tumors.
Fifteen pathogenic gen.nline mutations lcading to a truncated protcin product l l 'cre dctectcd
(15196, l6%). All mutation carriers had thcir f irst tumor diagnoscd undcr the age of 60 years;
l0 ofthem werc younger than 50 years at diagnosis. All had at lcast one colorectal canccr.






























































































Summttry, general discussion and future perspectives
above age 50 years. Twelve of the mutation carriers had one or more first-degree relatives
with an HNPCC-related cancer, predominantly colorectal or endometrial cancer. In six of 12
patients from families fulfilling the Amsterdam Criteria II a germline mutation was present.
MSI analysis missed three MSH6 mutation carriers; immunohistochemical analysis did not
miss any mutation. Based on our study results, it is concluded that in multiple HNPCC-related
cancer patients, selection for mutation analysis is best based on age at diagnosis of the first
tumor under 60 years of age, the presence of at least one colorectal cancer and
immunohistochemical analysis of the tumors for the MMR proteins.
In Chapter 5 the question was asked if adrenocortical adenocarcinoma should be added
to the HNPCC tumor spectrum. The question arose when one of the multiple cancer patients
described in Chapter 4 with an ovarian adenocarcinoma, three metachronous colorectal
cancers and an adrenocorlical adenocarcinoma turned out to be an MSH2 truncating mutation
carrier. Since the adrenal tumor was microsatellite-stable and no general loss of MSH2
protein in the adrenal tumor could be demonstrated, the development of this cancer should be
considered not to be associated with the germline MSH2 muÍation. Based on the findings in
this patient, there is no reason to include adrenocortical adenocarcinoma in the HNPCC-tumor
spectrum.
In Chapter 6 published studies on possible hereditary factors in the development of
endometrial cancer, especially in patients diagnosed under the age of 50 years, are reviewed.
In some patients with endometrial cancer, other cancers, such as colorectal cancer or ovarian
cancer, occur slmchronously or metachronously. This is, besides a positive family history and
a young age at diagnosis, indicative for a hereditary predisposition. HNPCC is now known to
be responsible for a small subset of endometrial cancers. This cancer is the second most
commonly occurring cancer in HNPCC. The question was which subset of young endometrial
cancer patients should be referred for genetic counseling. The answer is given in Chapter 7
and Chapter 8. In Chapter 7, use of immunohistochemical nalysis of MLHl and MSH2
proteins in selecting endometrial cancer patients for mutation analysis was examined. For this
purpose, immunohistochemical analysis was performed on normal and (pre)malignant
endometrial samples fror.n three groups of patients: L endometrial cancer patients with a
proven pathogenic MLHl or MSH2 germline mutation, 2. endometrial cancer patients without
such mutation but with a family, fulfilling the Amsterdam Criteria II, and 3. endometrial
cancer patients, not fulfilling these HNPCC criteria, diagnosed under the age of 50 years. A
strong relation could be shorvn in our study between presence of MLHI and MSH2 germline
mutations leading to a truncating protein product and the loss of corresponding protein
expression in endometrial cancer from MMR gene mutation carriers as found by
immunohistochemical analysis. This justifies the use of this type of analysis of these tumors
as a pre-screening method for mutation detection in clinically defined HNPCC families. The
loss of MLHl or MSH2 protein was also common in endometrial hyperplasia of MMR gene
mutation carriers as well as in endometrial hyperplasia of young endometrial cancer patients
in which no mutation had been detected; this indicates that loss of function of the MMR
proteins occurs early in carcinogenesis. In Chapter 8 we describe mutation analysis in an
extended series of 58 endometrial cancer patients diagnosed under the age of 50 years who
were unselected for family history. In five of them a truncating mutation was detected. In
addition to MLHI and MSH2 staining, performed in the study described in chapter 7, also
MSH6 immunol.ristochemical analysis was performed. In patients from families fulfilling the
revised Amsterdam Criteria the mutation rate was 50%. All five mutation carriers had a
strongly positive family history (four of the five patients came from families fulfilling the
149
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revised Amsterdam Criteria). Immunohistochemicai analysis predicted all tr-unciiting
mutations. MSI analysis missed one MSH6 mutation carrier. As a pre-screening method for
mutation analysis in young endometrial cancer patients immunohistochcmical nalysis in such
patients with at least one first-degree relative with an HNPCC-related cancer is valuable rvhile
MSI analysis in this series of young endometrial cancer patients has not proved to have
additional value over immunohistochemical nalysis.
The MSH6 gene is one of the MMR genes involvcd in HNPCC. ln lamilies fulf i l l ing the
Amsterdam Criteria the proportion of MSH6 germline mutations has been reporled to be
lower than the proportion of MLHI and MSII2 mutations.2("27 An explanation for the lower
frequency of MSH6 mutations in such families may be the fact that because of conrpensation
by other MMR proteins loss of the MSH6 function only causes a parlial loss of MMR
functioning and that for (a proporlion of) MSH6 mutations the penetrance of the genctic
predisposition may be lower than in case of mutations of MLHI or MSII2.ln order to further
define the molecular and clinical implications of M5116 germline varianls, all patients with
truncating and missense germline M5116 mutations that we detected are described in Chapter
9. Three hurrdred and sixteen individuals with (sr-rspicion of) HNPCC were analyzed for
MSH6 gennline mutations. Five different truncating MSÍ16 mutations, of which one was
detected seven times, were found in l2 index patients and ten MSH6 variants with unknorvn
pathogenicity were found ir.r another 13 index paticnts. For the 25 index paticnts and eight of
their relatives with MSH6 variants, molecular and clinical features are described. ln classical
Amsterdanr families the prevalence of MSI{6 mutations was about 10%o; most lamilies of
MSH6 mutation carriers, horvever, were atypical and belonged to what could bc callcd the
category of suspected HNPCC. In non-Arnsterdanr families, the prevalence of MSI{6 r,ariants
was estimatcd to be abotrt the same as the prcvalence of MLHI or MSÍ12 variants. A
substantial proporlion of tumors in MSH6 mutation carricrs did not show a l-righ degrec of
MSl. Twelve out of the total of 18 tumors from the twelve pathogenic MSI!6 mutation
caÍïiers showed absence of the MSH6 protein by immunohistochemical analysis. Female
cariers of MSH6 mutations appeared to be at a high risk for endornetrial cancer. The majority
of the colorectal cancers were localized distally in the colon. Missense variants in MSI16 werc
about as common as truncating mutations and, as there were no differences in nrolecular and
clinical characteristics, it is sr-rggested that a considerablc number of these nrissense variants
are also pathogenic. We conclude that for all HNPCC-suspccted patients lVtSHí nrutation
analysis should be considered and tl.rat neither MSI nor immunohistochen-rical analysis should
be a definitc selection critcrion for MSI{6 mutation analysis.
Besides ïhe hlLIII, MSI{2 and lvlsll5 gcnes two additional genes that havc reccntly
been'identihed u'ere analyzed for their possible role in HNPCC. Onc of these is EXOI.
Chapter l0 describes the detection of one splice-site mutation in an Amstcrdaur lamily and
eight nrissense EXOI gcne variants in l3 paticnts suspectcd of HNPCC. Analysis of DNA
lionr tumors from the variant carriers revealed only onc casc r'"i lhout EYOI allelic loss,
lvhereas 12 tunrors had lost the allclc rvith thc variant sequcncc and had retaincd thc uonlal
allele. As this secms in cor.rtradiction with current ideas of cancer dcvelopnient by MMR gcne
defects several rr.rodels rnay be possible to explain the afore-mentioned, among them a
haploinsufficiency model. A hapioirrsufficiency effect of EXOI in the tissues could cause
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rrould surnivc, but in some tissucs thc anrount of product from this singlc allele may be
insulÏcient to prevcnt cancer development.
In Chapter I I it rvas sl.to'"vr.t that the gene MLH3 might play a role in patients, suspected
of HNPCC. Ten different gcnnlinc M[,H3 variants, one lrameshifl mutation and nine
n"tissense variants, were detected in 12 patients with HNPCC suspicion. After performing MSI
analysis lvith nrono-, di- tri- and tetranuclcotide markcrs, mononucleotide markers did not
appear to be very infonr.rative. Using the five most infonr-rative repeat markers, including only
onc clinucleotide rnarker frorn the consensus panel of markers, the majority of the tumors
showed a high degree of MSI. With in"rrlunohistochcrnical analysis somatic irractivation of
Ihe lvlSll2, MLÍl I and M5Í16 gene was ruled out.
According to our present results, lhc EXOI and MLLI3 genes do not scern to play a significant
rolc in HNPCC. Predontinantly nrissetrse variants were lound in these genes. Functional
assays rvil l  be nceded to clarify thc role of these probably low-penetrant mutations in typical
and atypical HNPCC fanril ics.
GENERAI,  DISCUSSION
lrr paticnts u'ith colorcctal cancer and endometrial cancer diagnosed under the age of
50 years, t l ic prevalence o1-pathogenic germline mutations was less tl.ran l0'Zo while this was
1(r%, ir.r paticnts with mLLltiple HNPCC-associated cancers. In the three alorerrrentioned goups
a positive l ' irst-degree Íanrily history increased the risk of having a genr-rl ine mutation
markedly. Thc Anrstcrdan.r Critcria II showecl to have a low to nroderate sensitivity, at least in
thc groups oí'nrult iple canccr paticnts and yor-urg colorectal cancer patients. This was different
fbr young endonrctrial cancer patients as four of thc Ílve mutations were found in patients
ft 'onr Atnsterdanr II lanril ics. This is plausiblc, as the penetrance of endornetrial canccr in
HNPI'C lànril ies is lorver than that of colorcctal cancer, meaning that the presence of
cndonretrial cancer in HNPCC-sr.rspected farnil ies strongly indicates the prcscnce of 
-a
gcmrlinc NlMR gcnc nrutation, as was already shorvn in the study of Wijnen et ul (1998).')
Whcn the results of thc thrce paticnts groups that rve studied are combined (n-344 patients),
in about one third (8/25) of all fanril ies Iir lÍ-rl l ing thc Anrslerdam criteria l l  (AC Il) pathogcnic
tulLtaliot'ts occurcd. Tl.rcrenraining l6 mutations werc found in 319 non-Amsterdant lamilics.
' fhus,  thc sensi t iv i t l ,o f  thc Amsterdanr Cr i ter ia  I l  is  33.3 ' ló  (8 i24)  and the speci f ic i ty  is  95%
(303/320). fhe lor.r sensitivity of thc Amsterdanr Critcria Ii coLrld bc explained by the fact
that the slucly populalion was largcly unselected, in particular with rcspect to the lamily
history. Thc high specihcity is also l ikcly to be attributable to tl ie unselccted nature of the
population studied, r.rith only a snrall proportion of farnil ies fulf i l l ing the Amsterdarn Criteria
II. The positive prcdictive value o1- the Amsterdam Criteria II is only 32%. This may be
cxplained by the lact that parl of the mutation negative Amsterdam II lamilies included only 3
colorcctal canccr patients. Colorectal canccr occurs Íiequently in the general population and
clustering of colorectal carlcer by unknown genetic rncchanism may occur.
Our data i ldicatc that many nrutatiotrs would be nrissed when relying entirely upon the
Anrsterdanr Criteria Il and that thc decision to perforn'r mutation ar.ralysis hor-rld not be
cxclusively dependent on fulf i l l ing thcsc criteria. In Table I an approach is suggcsted to
better select paticnts at risk for harboring an MMR gennline mutation for mutation analysis.
On the othcr hand, rvhen a lanrily fulf i l ls the Amsterdan-r Criteria l l , genelic analysis should
be offered. of coursc.
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